LEXINGTON, Mass., May 14, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:
AGEN), an immuno-oncology company with an extensive pipeline of
agents designed to activate immune response to cancers and
infections, announced today that it will present data on AGEN1181
at the American Society of Clinical Oncology (ASCO) upcoming
ASCO2020 Virtual Scientific Program to be held May 29-31, 2020.
AGEN1181 is a multifunctional Fc-engineered next generation
anti-CTLA-4 antibody which has been designed to improve upon the
safety and efficacy shown with first-generation CTLA-4
antibodies.
The virtual presentation will be made by Dr. Steven J. O'Day, the Executive Director of
the John Wayne Cancer Institute and Cancer Clinic, and Director of
Providence Los Angeles Regional Research.
Abstract:
|
TPS3157
|
Title:
|
AGEN1181, A Clinical
Stage Fc-engineered anti-CTLA-4 Antibody with Improved Therapeutic
Potential for the Treatment of Patients with Advanced
Malignancies
|
Presenter:
|
Dr. Steven J.
O'Day
|
Session:
|
Developmental
Therapeutics—Immunotherapy
|
Date/Time:
|
May 29,
2020/8:00-11:00AM ET
|
Presentations will be available for on-demand viewing online
at
https://meetings.asco.org/am/virtual-program beginning
on May 29, 2020 at 8:00AM ET.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the
discovery and development of therapies that engage the body's
immune system to fight cancer and infections. The Company's vision
is to expand the patient populations benefiting from cancer
immunotherapy by pursuing combination approaches that leverage a
broad repertoire of antibody therapeutics, adoptive cell therapies
(through its AgenTus Therapeutics subsidiary), and proprietary
cancer vaccine platforms. The Company is equipped with a suite of
antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more information, please
visit www.agenusbio.com and our Twitter handle @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and twitter.
Forward-Looking Statements
This press release contains
forward-looking statements that are made pursuant to the safe
harbor provisions of the federal securities laws, including
statements regarding an upcoming presentation at ASCO on Agenus'
clinical data of AGEN1181 alone and in combination with balstilimab
(anti-PD-1). These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our most
recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K
filed with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
Contact:
Agenus Inc.
Jennifer
Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original
content:http://www.prnewswire.com/news-releases/agenus-nextgen-ctla-4-antibody-agen1181-data-to-be-presented-at-asco-301059304.html
SOURCE Agenus Inc.